Similar Papers

Paper Title
Journal
Date
Author
CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial
Timothy P Hughes ...
Clinical Lymphoma Myeloma and Leukemia | VOL. 22
Timothy P Hughes, et. al.Timothy P Hughes ...
01 Oct 2022
Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer.
F J Esteva ... K Koch
Journal of Clinical Oncology | VOL. 28
F J Esteva, et. al.F J Esteva ... K Koch
20 May 2010
Alk Inhibitor Ap26113 in Patients with Advanced Malignancies, Including Alk+ Non-Small Cell Lung Cancer (Nsclc): Updated Efficacy and Safety Data
S Gettinger ... G.J Weiss
Annals of Oncology | VOL. 25
S Gettinger, et. al.S Gettinger ... G.J Weiss
01 Sep 2014
Authors’ Reply
D Ross Camidge ... Rafal Dziadziuszko
Journal of Thoracic Oncology | VOL. 14
D Ross Camidge, et. al.D Ross Camidge ... Rafal Dziadziuszko
21 Aug 2019
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer
Baptiste Abbar ... Brigitte Autran
Journal of Thoracic Oncology | VOL. -
Baptiste Abbar, et. al.Baptiste Abbar ... Brigitte Autran
01 Feb 2025
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
Baohui Han ... Yusheng Wu
Journal of Thoracic Oncology | VOL. -
Baohui Han, et. al.Baohui Han ... Yusheng Wu
01 Feb 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. 20
--
01 Feb 2025
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li ... Yi-Long Wu
Journal of Thoracic Oncology | VOL. -
Yang-Si Li, et. al.Yang-Si Li ... Yi-Long Wu
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.